Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment

Cancer Imaging

Volumn 11, Issue SPEC. ISS. A, 2011, Pages

  Da Rosa, M R ^a   Trachtenberg, J ^b   Chopra, R ^c   Haider, M A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Focal therapy; High intensity focused ultrasound; Laser; Magnetic resonance imaging; Photodynamic therapy; Prostate cancer

Indexed keywords

PADOPORFIN; TEMOPORFIN;

ABLATION THERAPY; CANCER RADIOTHERAPY; CRYOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; LOW LEVEL LASER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; THERMAL ABLATION; TRANSRECTAL ULTRASONOGRAPHY; HUMAN; MALE; METHODOLOGY; PHOTOCHEMOTHERAPY; PROSTATE TUMOR;

HUMANS; LASER THERAPY; MAGNETIC RESONANCE IMAGING; MALE; PHOTOCHEMOTHERAPY; PROSTATIC NEOPLASMS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84866745041     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2011.9003     Document Type: Review

References (43)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: Cancer J Clinicians 2011; 61: 212-36. doi:10.3322/caac.20121.
2. Crawford ED, Barqawi A. Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. Oncology 2007; 21: 27-32; discussion 33-4, 39. (Pubitemid 46242753)
3. Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review. Curr Opin Urol 2009; 19: 283-9. doi:10.1097/MOU. 0b013e32832a2c4a.
4. Parker C, Muston D, Melia J, et al. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006; 94: 1361-8. doi:10.1038/sj.bjc.6603105. (Pubitemid 43772267)
5. Bill-Axelson A, Holmberg L, Fil-en F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54.
6. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8. doi:10.1056/NEJMoa0810084.
7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61. doi:10.1056/NEJMoa074311. (Pubitemid 351439226)
8. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 1358-67. (Pubitemid 39406169)
9. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31. doi:10.1200/JCO.2009.24.2180.
10. Anandadas CN, Clarke NW, Davidson SE, et al. Early prostate cancer-which treatment do men prefer and why? BJU Int 2011; 107: 1762-8. doi:10.1111/j.1464- 410X.2010.09833.x.
11. Cheng L, Jones TD, Pan C-X, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of smallvolume prostate cancer (50.5 ml) in whole-mount prostatectomy specimens. Modern Pathol 2005; 18: 1022-6. doi:10.1038/ modpathol.3800431. (Pubitemid 41224491)
12. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264-9. doi:10.1016/ S0090-4295(02)01728-4. (Pubitemid 34831770)
13. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 2003; 120: 386-91. doi:10.1309/ 82U1089XLQGKMMN1. (Pubitemid 37295109)
14. Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011; 14: 46-52. doi:10.1038/pcan.2010.16.
15. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007; 70(6 Suppl): 27-35. doi:10.1016/ j.urology.2007.06.1126.
16. Turkbey B, Pinto PA, Choyke PL. Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 2009; 6: 191-203. doi:10.1038/nrurol.2009.27.
17. Lindner U, Lawrentschuk N, Weersink RA, et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol 2010; 57: 1111-14. doi:10.1016/j.eururo.2010.03. 008.
18. Toi A, Neill MG, Lockwood GA, Sweet JM, Tammsalu LA, Fleshner NE. The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007; 177: 516-20. doi:10.1016/j.juro.2006.09.061. (Pubitemid 46054011)
19. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167: 2435-9. doi:10.1016/S0022-5347(05) 64999-3. (Pubitemid 34533140)
20. Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259: 162-72. doi:10.1148/radiol. 10101251.
21. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189: 323-8. doi:10.2214/AJR.07.2211. (Pubitemid 47195916)
22. Futterer JJ, Heijmink SW, Scheenen TWJ, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-58. doi:10.1148/radiol. 2412051866. (Pubitemid 44632891)
23. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002; 12: 2294-302. (Pubitemid 36940327)
24. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology 2010; 255: 485-94. doi:10.1148/ radiol.10091343.
25. Chopra R, Tang K, Burtnyk M, et al. Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Phys Med Biol 2009; 54: 2615-33. doi:10.1088/0031-9155/54/9/ 002.
26. Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia 2011; 27: 156-71. doi:10.3109/02656736.2010.518198.
27. Larson BT, Collins JM, Huidobro C, Corica A, Vallejo S, Bostwick DG. Gadolinium-enhanced MRI in the evaluation of minimally invasive treatments of the prostate: correlation with histopathologic findings. Urology 2003; 62: 900-4. doi:10.1016 /S0090-4295(03)00586-7. (Pubitemid 37421239)
28. Stafford RJ, Fuentes D, Elliott AA, Weinberg JS, Ahrar K. Laser-induced thermal therapy for tumor ablation. Crit Rev Biomed Eng 2010; 38: 79-100.
29. Raz O, Haider MA, Davidson SRH, et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 2010; 58: 173-7. doi:10.1016/j.eururo.2010.03.006.
30. Lindner U, Weersink RA, Haider MA, et al. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol 2009; 182: 1371-7. doi:10.1016/j.juro.2009.06.035.
31. Thuroff S, Chaussy C, Vallancien G, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003; 17: 673-7. doi:10.1089/089277903322518699. (Pubitemid 37362918)
32. Illing R, Emberton M. Sonablate-500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer. Expert Rev Med Devices 2006; 3: 717-29. doi:10.1586/ 17434440.3.6.717. (Pubitemid 46017612)
33. Sumitomo M, Asakuma J, Sato A, Ito K, Nagakura K, Asano T. Transurethral resection of the prostate immediately after highintensity focused ultrasound treatment for prostate cancer. Int J Urol 2010; 17: 924-30. doi:10.1111/j.1442- 2042.2010.02638.x.
34. Lukka H, Waldron T, Chin J, et al. High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol 2011; 23: 117-27. doi:10.1016/j.clon.2010.09.002.
35. Chopra R, Baker N, Choy V, et al. MRI-compatible transurethral ultrasound system for the treatment of localized prostate cancer using rotational control. Med Phys 2008; 35: 1346-57. doi:10.1118/1.2841937. (Pubitemid 351457502)
36. Chopra R, Burtnyk M, N-djin WA, Bronskill M. MRI-controlled transurethral ultrasound therapy for localised prostate cancer. Int J Hyperthermia 2010; 26: 804-21. doi:10.3109/ 02656736.2010.503670.
37. Siddiqui K, Chopra R, Vedula S, et al. MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology 2010; 76: 1506-11. doi:10.1016/j.urology.2010.04.046.
38. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg Med 2006; 38: 500-8. doi:10.1002/lsm.20337.
39. Trachtenberg J, Bogaards A, Weersink RA, et al. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007; 178: 1974-9; discussion 1979. doi:10.1016/j.juro.2007.07.036. (Pubitemid 47554440)
40. Nathan TR, Whitelaw DE, Chang SC, et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 2002; 168 (4 Pt 1): 1427-32. doi:10.1016/S0022-5347(05)64466-7. (Pubitemid 35034139)
41. Betrouni N, Lopes R, Puech P, Colin P, Mordon S. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11. Phys Med Biol 2011; 56: 4771-83. doi:10.1088/0031-9155/56/15/009.
42. Trachtenberg J, Weersink RA, Davidson SRH, et al. Vasculartargeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 2008; 102: 556-62. doi:10.1111/j.1464-410X.2008.07753.x.
43. Haider MA, Davidson SRH, Kale AV, et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 2007; 244: 196-204. doi:10.1148/radiol.2441060398. (Pubitemid 46981974)